Cardiol Therapeutics (CRDL) Projected to Post Earnings on Monday

Key Points

• Cardiol Therapeutics is set to report its Q2 2025 earnings on August 11th, with analysts predicting a loss of ($0.11) per share.
• The stock traded down 0.4% to $1.38, with a 12-month low of $0.77 and a high of $2.63.
• HC Wainwright has issued a "buy" rating for Cardiol Therapeutics, setting a price target of $9.00 for the stock.

Cardiol Therapeutics (NASDAQ:CRDL - Get Free Report) is projected to release its Q2 2025 earnings data before the market opens on Monday, August 11th. Analysts expect Cardiol Therapeutics to post earnings of ($0.11) per share for the quarter.

Cardiol Therapeutics Stock Down 0.4%

Shares of NASDAQ:CRDL traded down $0.01 during trading on Monday, hitting $1.38. The stock had a trading volume of 113,170 shares, compared to its average volume of 248,279. Cardiol Therapeutics has a 12 month low of $0.77 and a 12 month high of $2.63. The company has a quick ratio of 3.26, a current ratio of 3.26 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $113.69 million, a PE ratio of -4.04 and a beta of 1.05. The firm's fifty day moving average is $1.36 and its 200 day moving average is $1.21.

Wall Street Analyst Weigh In

Separately, HC Wainwright assumed coverage on Cardiol Therapeutics in a research report on Monday, June 2nd. They set a "buy" rating and a $9.00 price objective for the company.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.